GlaxoSmithKline: Herpes Simplex trials

The registry lists 20 Herpes Simplex studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 3Phase 3 7Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 YearsCompletedNCT05989672Phase 1Results posted
• A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital HerpesCompletedNCT05298254Phase 1/2Results posted
• Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation PatientsCompletedNCT01602562Phase 3Results posted
• Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years OldCompletedNCT00224484Phase 3Results posted
• VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.CompletedNCT00116844Phase 4Results posted
• HerpeVac Trial for Young WomenCompletedNCT00057330Phase 3Results posted
• A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 YearsTerminatedNCT04762511Phase 1
• Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella PertussisCompletedNCT01160081
• Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes DiseaseCompletedNCT00699764Phase 3
• Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive AdultsCompletedNCT00698893Phase 1
• Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative SubjectsCompletedNCT00698568Phase 3
• Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell LinesCompletedNCT00698490Phase 1/2
• Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without AdjuvantCompletedNCT00697567Phase 2
• A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And ChildrenCompletedNCT00297206Phase 1
• Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex VaccineCompletedNCT00224471Phase 3
• A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected PersonsTerminatedNCT00079911Phase 4
• A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected PatientsStatus unknownNCT00005663Phase 3
• The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected PatientsCompletedNCT00002404Not applicable
• A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected PatientsCompletedNCT00002084Not applicable
• A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected PatientsCompletedNCT00002000Not applicable